Purpose: To determine if lower urinary tract symptoms (LUTS) secondary to benign prostatic hypertrophy (BPH) can be effectively and safely treated by prostatic artery embolization (PAE) in men with glands 80-150 cm 3 . Materials: Inclusion criteria for enrollment included prostate volume 80-150 cm 3 , severe LUTS secondary to BPH and a low suspicion for prostate cancer. Baseline data included International Prostate Symptom Scoring (IPSS), Quality of Life score (QoL), International Index of Erectile Function (IIEF), maximum urine flow rate (Qmax), post-void residual volume (PVR), serum prostate specific antigen level (PSA) and prostate volume (PV). PAE was performed with 300-500 micron gelatin spheres. 1 and 3 mo follow-up data included IPSS, QoL, IIEF, PVR and Qmax. Cystoscopy and anoscopy were performed at 1 mo follow-up. Technical success was defined as bilateral embolization and clinical success was defined as 25% reduction of IPSS or 1 pt decrease in QoL. Results: Technical success was achieved in 100% (11/11) patients. Clinical success was 82% (9/11) at 1 mo and 88% (7/8) at 3 mo. See accompanying table for longitudinal data. There were only self-limiting minor complications including small access site hematoma (1/11), hematospermia (1/11), urinary retention (1/11) and urinary incontinence (2/11). Conclusions: PAE was safe and effective in this small cohort of men with prostate volume of 80-150 cm3. Conclusions: Review of results at 6 and 12 months following PAE for symptomatic BPH has shown statistically significant improvement in mean PV, PSA, PVR, Qmax, IPSS, and QoL. Few major complications were reported. These findings suggest that PAE is a promising alternative to TURP, however larger randomized-control trials with longer followup periods are required to further assess its effectiveness in clinical practice.
